HK1108163A1 - Antibodies that bind to epha2 and methods of use thereof - Google Patents
Antibodies that bind to epha2 and methods of use thereofInfo
- Publication number
- HK1108163A1 HK1108163A1 HK08101935.8A HK08101935A HK1108163A1 HK 1108163 A1 HK1108163 A1 HK 1108163A1 HK 08101935 A HK08101935 A HK 08101935A HK 1108163 A1 HK1108163 A1 HK 1108163A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- methods
- epha2
- antibodies
- bind
- antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65004705P | 2005-02-04 | 2005-02-04 | |
PCT/US2006/004057 WO2006084226A2 (en) | 2005-02-04 | 2006-02-06 | Antibodies that bind to epha2 and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1108163A1 true HK1108163A1 (en) | 2008-05-02 |
Family
ID=36778009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK08101935.8A HK1108163A1 (en) | 2005-02-04 | 2008-02-21 | Antibodies that bind to epha2 and methods of use thereof |
Country Status (17)
Country | Link |
---|---|
US (3) | US7569672B2 (xx) |
EP (1) | EP1846450B1 (xx) |
JP (1) | JP5342145B2 (xx) |
KR (1) | KR101363252B1 (xx) |
CN (2) | CN104059150B (xx) |
AT (1) | ATE551367T1 (xx) |
AU (1) | AU2006210460B2 (xx) |
BR (1) | BRPI0607450A2 (xx) |
CA (1) | CA2597198C (xx) |
CR (1) | CR9332A (xx) |
HK (1) | HK1108163A1 (xx) |
IL (1) | IL184803A (xx) |
MX (1) | MX2007009403A (xx) |
NO (1) | NO20074474L (xx) |
RU (1) | RU2007133108A (xx) |
WO (1) | WO2006084226A2 (xx) |
ZA (1) | ZA200707275B (xx) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7192698B1 (en) * | 1999-08-17 | 2007-03-20 | Purdue Research Foundation | EphA2 as a diagnostic target for metastatic cancer |
US6927203B1 (en) * | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
MX2007009403A (es) * | 2005-02-04 | 2007-10-02 | Raven Biotechnologies Inc | Anticuerpos que se unen a epha2 y metodos para usar los mismos. |
AU2006287416A1 (en) * | 2005-09-07 | 2007-03-15 | Medimmune, Llc | Toxin conjugated Eph receptor antibodies |
JP5622390B2 (ja) * | 2006-07-18 | 2014-11-12 | サノフイ | 癌治療用対epha2アンタゴニスト抗体 |
JP2010516259A (ja) | 2007-01-22 | 2010-05-20 | レイベン バイオテクノロジーズ | ヒトがん幹細胞 |
WO2008157490A1 (en) * | 2007-06-18 | 2008-12-24 | Medimmune, Llc | Synergistic treatment of cells that express epha2 and erbb2 |
MX2010002248A (es) | 2007-08-30 | 2010-03-25 | Daiichi Sankyo Co Ltd | Anticuerpos anti-epha2. |
WO2009085805A2 (en) * | 2007-12-21 | 2009-07-09 | Siemens Heathcare Diagnostics Inc. | Circulating epha2 receptor |
CN102046655B (zh) | 2008-04-02 | 2016-09-14 | 宏观基因有限公司 | Bcr-复合体-特异性抗体和其使用方法 |
JP5117917B2 (ja) | 2008-04-21 | 2013-01-16 | デクセリアルズ株式会社 | 保護素子及びその製造方法 |
US8715654B2 (en) | 2008-10-02 | 2014-05-06 | Celtaxsys, Inc. | Methods of modulating the negative chemotaxis of immune cells |
KR20110104032A (ko) | 2008-12-19 | 2011-09-21 | 마크로제닉스, 인크. | 공유결합형 디아바디 및 이의 용도 |
UY32914A (es) | 2009-10-02 | 2011-04-29 | Sanofi Aventis | Anticuerpos que se usan específicamente al receptor epha2 |
DK2498796T3 (en) | 2009-11-09 | 2018-03-05 | Aal Scient Inc | HEART DISEASE TREATMENT |
WO2011057251A2 (en) * | 2009-11-09 | 2011-05-12 | The Brigham And Women's Hospital, Inc. | Treatment of heart disease |
US8802091B2 (en) | 2010-03-04 | 2014-08-12 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
JP5998060B2 (ja) | 2010-03-04 | 2016-09-28 | マクロジェニクス,インコーポレーテッド | B7−h3と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用 |
KR20130048242A (ko) * | 2010-07-22 | 2013-05-09 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 항-종양 항원 항체 및 이용 방법 |
MX339622B (es) | 2010-08-02 | 2016-06-02 | Macrogenics Inc | Diacuerpos covalentes y sus usos. |
CA2836873C (en) | 2011-05-21 | 2019-10-22 | Macrogenics, Inc. | Deimmunized serum-binding domains and their use for extending serum half-life |
JP2015527869A (ja) | 2011-08-26 | 2015-09-24 | メリマック ファーマシューティカルズ インコーポレーティッド | タンデムFc二重特異性抗体 |
EP2764082B1 (en) * | 2011-10-04 | 2018-05-23 | Expression Pathology, Inc. | Srm/mrm assay for the ephrin type-a receptor 2 protein |
JP5875054B2 (ja) * | 2013-02-13 | 2016-03-02 | 国立大学法人 東京大学 | がんの検査方法及び検査用キット |
US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
US9458245B2 (en) | 2013-03-06 | 2016-10-04 | Merrimack Pharmaceuticals, Inc. | ANTI-C-MET tandem Fc bispecific antibodies |
KR20220025917A (ko) | 2014-05-29 | 2022-03-03 | 마크로제닉스, 인크. | 삼중-특이적 결합 분자 및 그것의 사용 방법 |
KR101636882B1 (ko) * | 2015-06-25 | 2016-07-06 | 전남대학교 산학협력단 | 인간 피브로넥틴 도메인 Ⅲ 기본 골격의 신규 인간 EphA2 특이적 결합 단백질 및 그의 용도 |
GEP20227419B (en) | 2015-07-30 | 2022-10-10 | Macrogenics Inc | Pd-1-binding molecules and methods of use thereof |
WO2017106061A1 (en) | 2015-12-14 | 2017-06-22 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof |
US11534466B2 (en) | 2016-03-09 | 2022-12-27 | Aal Scientifics, Inc. | Pancreatic stem cells and uses thereof |
BR112018071105A2 (pt) | 2016-04-15 | 2019-02-26 | Macrogenics, Inc. | conjugado de droga e anticorpo, molécula de ligação, composição farmacêutica e uso |
US20190359722A1 (en) * | 2017-01-23 | 2019-11-28 | Toyo University | Anti-epha2 antibody and immunological detection of epha2 using same |
SG11201907753TA (en) | 2017-02-24 | 2019-09-27 | Macrogenics Inc | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof |
BR112020011810A2 (pt) | 2017-12-12 | 2020-11-17 | Macrogenics, Inc. | molécula de ligação cd16 x antígeno de doença, composição farmacêutica, uso da composição farmacêutica, e método para o tratamento de uma doença |
SG11202007572VA (en) | 2018-02-15 | 2020-09-29 | Macrogenics Inc | Variant cd3-binding domains and their use in combination therapies for the treatment of disease |
JP7326764B2 (ja) * | 2018-03-09 | 2023-08-16 | 東ソー株式会社 | 腫瘍マーカーならびに腫瘍細胞を夾雑細胞と区別して回収および検出する方法 |
KR20220159289A (ko) | 2021-05-25 | 2022-12-02 | 주식회사 박셀바이오 | 모노바디 기반 키메라 항원 수용체 및 이를 포함하는 면역 세포 |
KR20230140746A (ko) * | 2022-03-30 | 2023-10-10 | 연세대학교 산학협력단 | 암전이의 검출용 신규 바이오마커 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5552391A (en) | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5824303A (en) | 1992-11-13 | 1998-10-20 | Amgen Inc. | Eck receptor ligands |
US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
US5532159A (en) | 1994-04-01 | 1996-07-02 | The Ohio State University | Monoclonal antibody to canine placental oncofetal protein for detecting cancer |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
CN1258539C (zh) | 1998-12-22 | 2006-06-07 | 雷文生物技术公司 | 用于产生特定类型细胞的代表性单克隆抗体的组合物及方法 |
JP2003516930A (ja) | 1999-08-17 | 2003-05-20 | パーデュー・リサーチ・ファウンデーション | 転移性疾患の治療 |
US6927203B1 (en) | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
EP1210603B1 (en) * | 1999-08-17 | 2010-10-06 | Purdue Research Foundation | Anti-epha2 antibodies as a cancer diagnostic |
US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
US6406840B1 (en) | 1999-12-17 | 2002-06-18 | Biomosaic Systems, Inc. | Cell arrays and the uses thereof |
US6541225B1 (en) | 2000-01-26 | 2003-04-01 | Raven Biotechnologies, Inc. | Methods and compositions for generating human monoclonal antibodies |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
FR2838742B1 (fr) | 2002-04-23 | 2004-07-09 | Inst Nat Sante Rech Med | Epitopes t de l'antigene epha2 |
WO2004014292A2 (en) | 2002-05-10 | 2004-02-19 | Purdue Research Foundation | EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF |
ATE525398T1 (de) | 2002-05-10 | 2011-10-15 | Medimmune Inc | Epha2 monoklonale antikörper und deren anwendungsverfahren |
MX2007009403A (es) | 2005-02-04 | 2007-10-02 | Raven Biotechnologies Inc | Anticuerpos que se unen a epha2 y metodos para usar los mismos. |
-
2006
- 2006-02-06 MX MX2007009403A patent/MX2007009403A/es active IP Right Grant
- 2006-02-06 AU AU2006210460A patent/AU2006210460B2/en not_active Ceased
- 2006-02-06 WO PCT/US2006/004057 patent/WO2006084226A2/en active Application Filing
- 2006-02-06 CN CN201410213409.1A patent/CN104059150B/zh not_active Expired - Fee Related
- 2006-02-06 KR KR1020077019628A patent/KR101363252B1/ko active IP Right Grant
- 2006-02-06 EP EP06734397A patent/EP1846450B1/en not_active Not-in-force
- 2006-02-06 BR BRPI0607450-2A patent/BRPI0607450A2/pt not_active Application Discontinuation
- 2006-02-06 CN CN200680011089.5A patent/CN101155830B/zh not_active Expired - Fee Related
- 2006-02-06 JP JP2007554287A patent/JP5342145B2/ja not_active Expired - Fee Related
- 2006-02-06 ZA ZA200707275A patent/ZA200707275B/xx unknown
- 2006-02-06 CA CA2597198A patent/CA2597198C/en not_active Expired - Fee Related
- 2006-02-06 US US11/349,327 patent/US7569672B2/en not_active Expired - Fee Related
- 2006-02-06 AT AT06734397T patent/ATE551367T1/de active
- 2006-02-06 RU RU2007133108/13A patent/RU2007133108A/ru not_active Application Discontinuation
-
2007
- 2007-07-24 IL IL184803A patent/IL184803A/en not_active IP Right Cessation
- 2007-08-22 CR CR9332A patent/CR9332A/es not_active Application Discontinuation
- 2007-09-03 NO NO20074474A patent/NO20074474L/no not_active Application Discontinuation
-
2008
- 2008-02-21 HK HK08101935.8A patent/HK1108163A1/xx not_active IP Right Cessation
-
2009
- 2009-06-30 US US12/495,218 patent/US7776328B2/en not_active Expired - Fee Related
- 2009-11-30 US US12/627,335 patent/US8183357B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
MX2007009403A (es) | 2007-10-02 |
CN104059150A (zh) | 2014-09-24 |
IL184803A0 (en) | 2007-12-03 |
US20090263391A1 (en) | 2009-10-22 |
KR101363252B1 (ko) | 2014-02-13 |
US20060177453A1 (en) | 2006-08-10 |
CN104059150B (zh) | 2018-10-02 |
EP1846450A2 (en) | 2007-10-24 |
US20100086969A1 (en) | 2010-04-08 |
ATE551367T1 (de) | 2012-04-15 |
EP1846450B1 (en) | 2012-03-28 |
US8183357B2 (en) | 2012-05-22 |
KR20070107721A (ko) | 2007-11-07 |
WO2006084226A2 (en) | 2006-08-10 |
RU2007133108A (ru) | 2009-03-10 |
BRPI0607450A2 (pt) | 2009-09-01 |
WO2006084226A3 (en) | 2006-11-30 |
JP2008529497A (ja) | 2008-08-07 |
JP5342145B2 (ja) | 2013-11-13 |
CR9332A (es) | 2008-03-18 |
CA2597198A1 (en) | 2006-08-10 |
CN101155830B (zh) | 2014-06-18 |
CN101155830A (zh) | 2008-04-02 |
AU2006210460A1 (en) | 2006-08-10 |
US7776328B2 (en) | 2010-08-17 |
ZA200707275B (en) | 2009-01-28 |
AU2006210460B2 (en) | 2012-04-05 |
NO20074474L (no) | 2007-11-05 |
EP1846450A4 (en) | 2008-05-28 |
US7569672B2 (en) | 2009-08-04 |
IL184803A (en) | 2011-04-28 |
AU2006210460A2 (en) | 2006-08-10 |
CA2597198C (en) | 2016-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1108163A1 (en) | Antibodies that bind to epha2 and methods of use thereof | |
SG170728A1 (en) | Anti-tumor cell antigen antibody therapeutics | |
HK1064621A1 (en) | Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof | |
HK1074634A1 (en) | Internalizing antibodies specific for the raag10 cell surface target | |
DK2097453T3 (da) | Monoklonale antistoffer mod humant Anti-Müllerian Hormon type II receptor (AMHR-II) | |
EP1996716A4 (en) | MODIFIED ANTIBODIES AGAINST THE ANTIGEN OF PROSTATIC STEM CELLS FOR TARGETING CANCER | |
WO2008066691A3 (en) | Tes7 and antibodies that bind thereto | |
WO2006084078A3 (en) | Jam-3 and antibodies that bind thereto | |
UA106194C2 (ru) | Диагностика и лечение рака с применением антитела к ereg | |
WO2006084092A3 (en) | Antibodies to oncostatin m receptor | |
WO2006076584A3 (en) | Kid31 and antibodies that bind thereto | |
DE602006013029D1 (de) | Anti-egfr-antikörper | |
NZ601615A (en) | Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor | |
IN2014MN00873A (xx) | ||
PL1851250T3 (pl) | Ludzkie przeciwciało monoklonalne przeciwko antygenowi błony komórkowej komórek prostaty (PSMA) | |
WO2006110745A3 (en) | Conjugated anti-psma antibodies | |
MX2010001237A (es) | Nuevos anticuerpos. | |
UA94211C2 (ru) | Выделенное полностью человеческое моноклональное cd3 антитело | |
NZ583894A (en) | Antibodies that bind to a non atp binding p2x7 receptor | |
WO2011119888A3 (en) | N-cadherin: target for cancer diagnosis and therapy | |
ZA202008095B (en) | Humanized antibodies against psma | |
WO2004101762A3 (en) | Detection and treatment of cancers of the colon | |
WO2003024302A3 (en) | Detection and treatment of cancers of breast | |
UA98632C2 (ru) | Антагонистические антитела к notch3 и их применение для профилактики и лечения связанных с notch3 заболеваний | |
SI1461360T1 (sl) | Konjugati, ki obsegajo protitelo, specifično za domeno ED-B fibronektina, in njihova uporaba za detekcijo in zdravljenje tumorjev |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20200202 |